HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and…
$15.16+6.76%
报价 2026-11-06
市值
$2.64B
EV
$2.32B
PE (TTM)
145.0x
预期 PE (FY2026)
42.3x
52 周区间距高点 -5.5%
$9.99$16.05
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Drug Manufacturers - Specialty & Generic| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| HCMHutchison China Ltd. | $2.64B | +6.8% | +10.9% | 17% | 145.0x | – | 234.4x | |
| BHCBausch Health Companies Inc. | $3.06B | +2.8% | +7.5% | 75% | – | 8.9x | 1.7x | |
| RGCRegencell Bioscience Holdings Limited | $2.61B | -2.8% | – | 0% | – | – | – | |
| PRGOPerrigo Company plc | $2.2B | +0.9% | -6.0% | 30.7% | – | – | 12.9x | |
| TRLVTrulieve Cannabis Corp. | $1.97B | +6.1% | -15.1% | 59.9% | – | 6.8x | 8.2x | |
| ALVOAlvotech | $1.73B | +6.8% | +1.1% | 50.7% | – | – | – | |
| ANIPANI Pharmaceuticals, Inc. | $1.55B | -3.2% | +27.2% | 61.6% | 13.0x | 5.3x | 8.1x | Cheap GARP |
| SUPNSupernus Pharmaceuticals, Inc. | $1.52B | -2.2% | +25.9% | 85.7% | 7.1x | 3.0x | 49.1x | Cheap GARP |
| PCRXPacira BioSciences, Inc. | $1.45B | +0.0% | +3.3% | 77% | 103.2x | 14.4x | 8.1x | |
| 同行中位数 | – | – | +3.3% | 60.8% | 13.0x | 6.8x | 8.1x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $139.1M | $139.1M | $135.4M | $135.4M | $138.8M | $138.8M | $162.3M | $162.3M |
| Gross Margin | 17% | 17% | -17.1% | -17.1% | 39.7% | 39.7% | -17.4% | -17.4% |
| Operating Margin | 0.3% | 0.3% | -13.2% | -13.2% | -1.3% | -1.3% | -5% | -5% |
| Net Income | $8M | $8M | $977,500 | $977,500 | $227.5M | $227.5M | $6M | $6M |
| Diluted EPS | 0.05 | 0.05 | 0.01 | 0.01 | 1.3 | 1.3 | 0.04 | 0.04 |
| Operating Cash Flow | $6.1M | $6.1M | $4.1M | $4.1M | $-36.4M | $-36.4M | $20.2M | $20.2M |
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。